Status:
COMPLETED
Trial of Liposomal Doxorubicin (Doxil) and Weekly Docetaxel (Taxotere)
Lead Sponsor:
University of Southern California
Collaborating Sponsors:
Tibotec Therapeutics, a Division of Ortho Biotech Products, L.P., USA
Conditions:
Cancer
Carcinoma
Eligibility:
All Genders
18+ years
Phase:
PHASE1
Brief Summary
This study is for patients with advanced cancer that has failed treatment with conventional therapy or for which no standard treatment exists. The purpose of this study is to determine the highest dos...
Eligibility Criteria
Inclusion
- Histological proof of advanced or recurrent solid tumor which has failed prior therapy, or for which no effective therapy is available.
- Ovarian cancer patients (or primary peritoneal carcinoma) whose only manifestation of disease is an elevated cancer antigen (CA) 125 of \> 100 are eligible.
- SWOG performance status 0-2.
- Absolute granulocyte count (AGC) greater than or equal to 1.5; platelets greater than or equal to 100,000.
- Total bilirubin less than or equal to the upper limit of normal (ULN).
- Transaminases (SGOT and/or SGPT) may be up to 2.5 x institutional upper limit of normal (ULN) if alkaline phosphatase is \<= ULN, or alkaline phosphatase may be up to 4 x ULN if transaminases are \<= ULN. However, patients who have both transaminase elevation \> 1.5 x ULN and alkaline phosphatase \> 2.5 x ULN are not eligible for this study (due to decreased clearance of docetaxel and increased risk of toxicity).
- Age greater than or equal to 18 years.
- Fully recovered from acute toxicities from chemotherapy, radiation, or surgery.
- Negative serum pregnancy test, if patient is female, still fertile, and sexually active.
Exclusion
- Prior treatment with Doxil or weekly docetaxel. Prior docetaxel administered every 3 weeks is allowed.
- Evidence of moderate peripheral neuropathy greater than or equal to grade 2.
- Medical, social, or psychological factors interfering with compliance.
- Known history of cardiac disease (congestive heart failure, coronary artery disease) that would preclude treatment with Doxil in the opinion of the investigator.
- Cardiac ejection fraction \< 50%
- Pregnancy
Key Trial Info
Start Date :
December 1 2000
Trial Type :
INTERVENTIONAL
End Date :
May 1 2006
Estimated Enrollment :
35 Patients enrolled
Trial Details
Trial ID
NCT00183742
Start Date
December 1 2000
End Date
May 1 2006
Last Update
May 22 2014
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
U.S.C./Norris Comprehensive Cancer Center
Los Angeles, California, United States, 90033